Literature DB >> 35814609

Cross-Sectional Survey of High-Risk Pregnant Women's Opinions on COVID-19 Vaccination.

Marcia DesJardin1, Edward Raff2,3, Nicholas Baranco1, Dimitrios Mastrogiannis1.   

Abstract

Background: Pregnant women are at increased risk of severe disease with coronavirus disease 2019 (COVID-19). Despite strong recommendations from American College of Obstetricians and Gynecologists and Society for Maternal Fetal Medicine for vaccination, COVID-19 vaccination hesitancy persists. With this study, we aim to evaluate opinions about the COVID-19 vaccine in a cohort of high-risk pregnant patients. Materials and
Methods: Institutional review board approval was obtained. Patients attending a regional Maternal-Fetal Medicine clinic in central New York were surveyed about the COVID-19 vaccine using a standardized questionnaire. Demographic, obstetrical, and medical information was abstracted using medical records. The vaccinated and unvaccinated groups were evaluated using chi-square tests and a Bayesian model.
Results: Among the 157 participants, 38.2% are vaccinated. There were no significant differences in race/ethnicity, living situation, marital status, employment status, insurance type, pregravid body mass index, history of recreational drug use, number of living children, or gestational age at the time of survey. Patients with less formal education are less likely to be vaccinated. There was no difference between influenza and tetanus diphtheria pertussis vaccination rates with COVID-19 vaccination rates. Unvaccinated patients cite lack of data in pregnancy (66%) as their primary concern. Most patients prefer to learn about vaccines via conversation with their doctor (46.7% for vaccinated and 59.8% for unvaccinated). Conclusions: The vaccination rate is low in our population. A provider-initiated conversation about COVID-19 vaccination included with routine prenatal care could increase the vaccination rate. © Marcia DesJardin et al., 2022; Published by Mary Ann Liebert, Inc.

Entities:  

Keywords:  COVID; pregnancy; vaccination

Year:  2022        PMID: 35814609      PMCID: PMC9258791          DOI: 10.1089/whr.2022.0006

Source DB:  PubMed          Journal:  Womens Health Rep (New Rochelle)        ISSN: 2688-4844


Introduction

Pregnant women are at increased risk of severe disease with infectious viruses.[1] With coronavirus disease 2019 (COVID-19) infection, pregnant women are more likely to be admitted to an intensive care unit, require invasive ventilation, and die[2,3] compared with nonpregnant subjects. Despite these statistics, there is widespread distrust with the vaccine and lack of vaccination in pregnant women. By May 2021, 46% of reproductive-aged women received one dose of the COVID-19 vaccine, whereas only 16% of pregnant women had done the same.[4,5] The vaccination rate of pregnant women rose to only 33% by October 1, 2021 despite multiple efforts to improve access and information about the vaccination.[6-14] Pregnant women were excluded from initial COVID-19 vaccination clinical trials.[1,12] As a result, initial recommendations for the vaccines were mostly empiric for pregnant women, primarily based on observational real data and resulted in a great amount of confusion and concern (with the additive effect of politization). The Centers for Disease Control (CDC) has an ongoing registry (V-Safe) to collect data regarding vaccination outcomes in pregnancy.[13] Since the onset of V-safe, studies that compiled the results of the registry demonstrated safety in pregnancy.[14] The American College of Obstetricians and Gynecologists (ACOG), Society for Maternal Fetal Medicine (SMFM), and CDC all published statements strongly in support of vaccination against COVID-19 in all women, including pregnant and lactating patients.[15-30] The mistrust created by the early trial designs and exacerbated by social media leaves pregnant women and fetuses vulnerable during this pandemic. COVID-19 infection has been shown to cause more severe disease in patients with existing comorbidities, such as obesity, hypertension, diabetes mellitus, and asthma.[31,32] With the additional baseline risk of severe disease in pregnancy, there is an increasing risk of severe disease if infected with COVID-19 in pregnant patients. With this study, we aim to evaluate opinions about the COVID-19 vaccine in a sample of high-risk pregnant patients in central New York.

Materials and Methods

Institutional review board approval was obtained (IRB No. 1722484-1, approved June 6, 2021). All patients who presented for prenatal care at a central New York regional Maternal–Fetal Medicine clinic September to October 2021 while a research staff member was present were invited to participate. Participants were excluded if they met exclusion criteria: age <18 years, unable to understand English, or incarcerated (Fig. 1). Convenience sampling was used due to ease of logistics with limited resources.
FIG. 1.

Prisma diagram.

Prisma diagram. The research staff member administered the survey to all available participants for four sequential weeks during all clinic hours except Fridays before noon. After informed consent was obtained, patients answered a standardized survey about the COVID-19 vaccine and demographic information. The survey was modeled after information gathered by Kaiser Family Foundation for national general population trends about COVID-19 vaccination hesitancy.[33] Participants were given a tablet to self-administer the written survey while a research staff member was available for clarification questions. The survey was available only in English. Further demographic, obstetrical, and medical information was abstracted using medical records. Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted by SUNY Upstate Medical University.[34,35] The COVID-19 vaccination status was used to identify the primary outcome. The vaccinated and unvaccinated groups were evaluated with a hierarchical Bayesian model. An effect size was generated via the Bayesian model; a credible interval that did not include zero was considered statistically significant.

Results

A total of 178 pregnant women were invited to participate in the study. Twenty-one participants were excluded; 16 declined to participate, 4 were unable to understand English, and 1 was <18 years old (Fig. 1). One hundred fifty-seven pregnant women were included in the analysis, for an 88% response rate (Table 1). All participants completed the survey provided. 38.2% reported that they received the COVID-19 vaccine. The most common reason for vaccine hesitancy was the lack of data about the vaccination in pregnancy (Fig. 2).
Table 1.

Categorical Abstracted Information, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status

CharacteristicsTotal (%)Vaccinated, n (%)Not vaccinated, n (%)Bayesian model: effect size (95% CI)[a]
Total157 (100%)60 (38.2)97 (61.7)n/a
Race and ethnicity
 Asian81 (12.5)7 (87.5)−1.04 (−3.05 to 1.07)
 Non-Hispanic White11649 (42.4)67 (57.8)0.85 (−1.03 to 2.67)
 Hispanic85 (62.5)3 (37.5)1.02 (−1.03 to 3.09)
 Non-Hispanic Black172 (11.8)15 (88.2)−0.33 (−2.38 to 1.69)
 American Indian/Alaskan Native20 (0)2 (100)−0.54 (−2.83 to 1.68)
 Other52 (40)3 (60)0.24 (−1.68 to 2.24)
Living situation
 Own home6632 (48.5)34 (51.5)0.12 (−1.81 to 1.94)
 Rent home7321 (28.8)52 (71.2)−0.27 (−2.09 to 1.55)
 Family household187 (38.9)11 (61.1)−0.12 (−1.99 to 1.81)
Employment status
 Full time7631 (40.8)45 (59.2)−0.30 (−2.07 to 1.56)
 Part time1811 (61.1)7 (38.9)0.73 (−1.21 to 2.65)
 Other113 (27.2)8 (72.7)−0.98 (−2.92 to 0.94)
 Unemployed4413 (29.5)31 (70.5)−0.28 (−2.11 to 1.54)
 Disabled62 (33.3)4 (66.7)0.38 (−1.63 to 2.47)
 Declined to state20 (0)2 (100)−0.14 (−2.54 to 2.15)
Level of education
 <8th grade20 (0)2 (100)−2.36 (−4.34 to −0.31)
 9–11th grade163 (18.8)13 (81.3)−1.24 (−2.67 to 0.26)
 High school or GED5314 (26.4)39 (73.6)−0.54 (−1.84 to 0.77)
 Vocational or technical school71 (14.3)6 (85.7)0.03 (−1.19 to 1.28)
 Associate degree or some college3818 (47.4)20 (52.6)0.62 (−0.58 to 1.92)
 Bachelor's degree2213 (59.1)9 (40.9)1.38 (−0.05 to 2.86)
Insurance type
 Medicaid or Medicare7519 (25.3)56 (74.7)−0.36 (−2.00 to 1.39)
 Private insurance8240 (48.8)42 (51.2)0.05 (−1.63 to 1.78)
Substance use
 No drug use11148 (43.2)63 (56.8)0.42 (−1.29 to 2.07)
 Current drug use111 (9.1)10 (90.9)−0.80 (−2.71 to 0.96)
 Former drug use3310 (30.3)23 (69.7)−0.61 (−2.28 to 1.14)
 Unknown drug use43 (75)1 (25)0.42 (−1.29 to 2.07)
Marital status
 Single6620 (30.3)46 (69.7)−0.22 (−2.09 to 1.64)
 Married7432 (43.2)42 (56.8)−0.50 (−2.34 to 1.35)
 Living as married116 (54.5)5 (45.5)0.52 (−1.43 to 2.50)
 Divorced22 (100)0 (0)0.53 (−1.55 to 2.70)
 Separated40 (0)4 (100)−0.48 (−2.66 to 1.71)
Method to learn more
 Provider conversation8628 (32.6)58 (67.4)−0.79 (−1.55 to −0.08)
 Pamphlet4010 (25)30 (75)−1.24 (−2.08 to −0.47)
 Prerecorded videos116 (54.5)5 (45.4)0.42 (−0.73 to 1.59)
 Social media2412 (50)12 (50)0.55 (−0.38 to 1.56)
 Webinar96 (66.7)3 (33.3)0.44 (−0.79 to 1.59)
 Written on website3817 (44.7)21 (55.3)0.12 (−0.69 to 0.98)
Infectious disease status
 Received flu vaccine3015 (50)15 (50)0.18 (−0.59 to 0.95)
 Received Tdap vaccine6121 (34.4)40 (65.6)0.61 (−0.25 to 1.45)
 Previous positive COVID test62 (33.3)4 (66.7)0.08 (−0.47 to 0.65)

CI, credible interval; COVID-19, coronavirus disease 2019; Tdap, tetanus diphtheria pertussis.

Bayesian model included in Figure 3.

FIG. 2.

Reasons for lack of vaccination.

Reasons for lack of vaccination. Categorical Abstracted Information, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status CI, credible interval; COVID-19, coronavirus disease 2019; Tdap, tetanus diphtheria pertussis. Bayesian model included in Figure 3.
FIG. 3.

Hierarchical logistic Bayesian regression.

A hierarchical Bayesian logistic regression was performed to control for multiple variables simultaneously based on conditional probabilities (Fig. 3). This model suggests that vaccinated individuals were slightly older (effect size 0.84 [95% credible interval; CI: 0.32–1.36]) (Fig. 3 and Table 1). Hierarchical logistic Bayesian regression. There were no significant differences in race/ethnicity (Asian: −1.04 [95% CI: −3.05 to 1.07], non-Hispanic White: 0.85 [95% CI: −1.03 to 2.67], Hispanic: 1.02 [95% CI: −1.03 to 3.09], non-Hispanic Black: −0.33 [95% CI: −2.38 to 1.69], American Indian/Alaskan Native: −0.54 [95% CI: −2.83 to 1.68], other: 0.24 [95% CI: −1.68 to 2.24]); living situation (own home: 0.12 [95% CI: −1.81 to 1.94], rent home: −0.27 [95% CI: −2.09 to 1.55], live in family household: −0.12 [95% CI: −1.99 to 1.81]); marital status (single: −0.22 [95% CI: −2.09 to 1.64], married: −0.50 [95% CI: −2.34 to 1.35], living as married: 0.52 [95% CI: −1.43 to 2.50], divorced: 0.52 [95% CI: −1.43 to 2.50], separated: −0.48 [95% CI: −2.66 to 1.71]). There was no difference in employment status (full time: −0.30 [95% CI: −2.07 to 1.56], part time: 0.73 [95% CI: −1.21 to 2.65], other: −0.98 [95% CI: −2.92 to 0.94], unemployed: −0.28 [95% CI: −2.11 to 1.54], disabled: 0.38 [95% CI: −1.63 to 2.47]); insurance type (Medicaid or Medicare: −0.36 [95% CI: −2.00 to 1.39], private insurance: 0.05 [95% CI: −1.63 to 1.78]); history of recreational drug use (no drug use: 0.42 [95% CI: −1.29 to 2.07], current drug use: −0.80 [95% CI: −2.71 to 0.96], former drug use: −0.61 [95% CI: −2.28 to 1.14], unknown drug use: 0.42 [95% CI: −1.29 to 2.07]) (Fig. 3 and Table 1). There were no differences in pregravid body mass index (0.13 [95% CI: −0.28 to 0.55]), number of living children (−1.02 [95% CI: −1.44 to −0.58]), or gestational age at the time of survey (−0.06 [95% CI: −0.19 to 0.07]) between vaccinated and unvaccinated groups (Fig. 3 and Table 2).
Table 2.

Continuous Abstracted Information, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status

CharacteristicsVaccinated: mean (standard deviation)Not vaccinated: mean (standard deviation)Bayesian model: effect size (95% CI)[a]
Age, years30.6 (± 5.6)28.9 (± 5.8)0.84 (0.32 to 1.36)
Pregravid body mass index, kg/m230.9 (± 9.2)31.4 (± 9.0)0.13 (−0.28 to 0.55)
Gestational age range, weeks28 0/7–29 6/7[b]26 0/7–27 6/7[b]−0.06 (−0.19 to 0.07)
No. of living children1 (± 1)2 (± 2)−1.02 (−1.44 to −0.58)

Bayesian model included in Figure 3.

Standard deviation unable to be calculated.

Continuous Abstracted Information, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status Bayesian model included in Figure 3. Standard deviation unable to be calculated. We identified a trend that patients with less education were less likely to be vaccinated (less than eighth grade completed: −2.36 [95% CI: −4.34 to −0.31], ninth to eleventh grade: −1.24 [95% CI: −2.67 to 0.26], high school or GED: −0.54 [95% CI: −1.84 to 0.77], vocational or technical school: 0.03 [95% CI: −1.19 to 1.28], associate degree or some college: 0.62 [95% CI: −0.58 to 1.92], and bachelor's degree: 1.38 [95% CI: −0.05 to 2.86]) (Fig. 3 and Table 1). Patients with an eighth-grade level education or less were the least likely to have been vaccinated. Vaccination rates increase with increasing level of education. There was no correlation between COVID-19 vaccine rates and influenza (0.18 [95% CI: −0.59 to 0.95]) or tetanus diphtheria pertussis (Tdap) vaccination rates (0.61 [95% CI: −0.25 to 1.45]) (Fig. 3 and Table 1). Fifty percent of both the COVID-19 vaccinated and unvaccinated groups received the 2021 influenza vaccine. 65.6% of COVID-19 unvaccinated participants received the Tdap vaccine during pregnancy, whereas only 34.4% of COVID-19 vaccinated participants had. Six participants had a previous positive COVID-19 test on file; four of these participants remained unvaccinated at the time of survey (0.08 [95% CI: −0.47 to 0.65]) (Fig. 3 and Table 1). This was not statistically significant, likely because of the small number of participants with a positive test. The high-risk clinic population was selected to capture pregnant patients with medical comorbidities. Conditions that qualified an individual for early vaccination during the stratified rollout in New York Status were evaluated. It was hypothesized that vaccination rates would be higher in these high-risk individuals. Diabetes was the only medical comorbidity associated with a higher vaccination rate (1.30 [95% CI: 0.25–2.29]) (Fig. 3 and Table 3).
Table 3.

Medical Comorbidities by Vaccinated Versus Unvaccinated Status, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status

CharacteristicsTotal (%)Vaccinated, n (%)Not vaccinated, n (%)Bayesian model: effect size (95% CI)[a]
Hypertension206 (30.0)14 (70.0)−0.29 (−1.44 to 0.83)
Diabetes mellitus2716 (59.3)11 (40.7)1.30 (0.25 to 2.29)
Asthma4012 (30.0)28 (70.0)−0.54 (−1.67 to 0.54)
Other heart conditions92 (22.2)7 (77.8)−0.31 (−1.50 to 0.98)
Cancer10 (0)1 (100)−0.14 (−1.81 to 1.45)
Chronic kidney disease0000.00 (−1.59 to 1.62)
Other pulmonary disease31 (33.3)2 (66.7)−0.21 (−1.71 to 1.18)
Intellectual and developmental disabilities000−0.01 (−1.65 to 1.67)
Immunocompromised states62 (33.3)4 (66.7)−0.45 (−1.86 to 0.99)
Sickle cell disease or thalassemia10 (0)1 (100)−0.07 (−1.64 to 1.68)
Cerebrovascular disease0000.01 (−1.57 to 1.67)
Neurological conditions42 (50.0)2 (50.0)0.53 (−0.88 to 1.96)
Liver disease73 (42.9)4 (57.1)0.28 (−1.05 to 1.61)

Bayesian model included in Figure 3.

Medical Comorbidities by Vaccinated Versus Unvaccinated Status, by Coronavirus Disease 2019 Vaccinated Versus Not Vaccinated Status Bayesian model included in Figure 3. No other medical comorbidity correlated with COVID-19 vaccination status (hypertension: −0.29 [95% CI: −1.44 to 0.83], asthma: −0.54 [95% CI: −1.67 to 0.54], other heart conditions: −0.31 [95% CI: −1.50 to 0.98], cancer: −0.14 [95% CI: −1.81 to 1.45], chronic kidney disease: 0.00 [95% CI: −1.59 to 1.62], other pulmonary disease: −0.21 [95% CI: −1.71 to 1.18], intellectual and developmental disabilities: −0.01 [95% CI: −1.65 to 1.67], immunocompromised states: −0.45 [95% CI: −1.86 to 0.99], sickle cell disease or thalassemia: −0.07 [95% CI: −1.64 to 1.68], cerebrovascular disease: 0.01 [95% CI: −1.57 to 1.67], neurological conditions: 0.53 [95% CI: −0.88 to 1.96], and liver disease: 0.28 [95% CI: −1.05 to 1.61]) (Fig. 3 and Table 3). When given different options to learn more about the vaccine, most patients in both groups preferred to learn more about the vaccine via a conversation with their doctor (Fig. 4).
FIG. 4.

Patients answered how they would prefer to learn more about vaccinations.

Patients answered how they would prefer to learn more about vaccinations.

Discussion

The vaccination rate of our cohort is higher than the published national vaccination rates in pregnant women[3] although is still low. A lack of data in pregnancy is the most common cited reason for being unvaccinated. Despite strong recommendations by the experts in the field and subsequent studies demonstrating safety in pregnancy,[14,28-30] patients continue to express this concern. The exclusion of pregnant women in the first COVID-19 vaccination trials[1,12] propagated a sentiment of fear and danger that persists. An element of politics also appeared to be influencing the decision to get vaccinated or not. However, this study was not designed to address this issue and currently cannot be quantified. Less formal education correlates with a decrease in vaccination. This is consistent with international trends of COVID-19 vaccination hesitancy,[36,37] but unlike vaccination trends seen with childhood vaccination.[38] Increasing age is associated with increased COVID-19 vaccination rates. This may represent patients who have completed more formal education. It is unlikely that patients with a less formal education prioritize reading the latest scientific information about COVID-19 vaccination in pregnancy; this may impact the trend seen. Influenza vaccination is recommended universally to pregnant patients due to concern for increased severe illness from influenza.[39] Tdap vaccination is recommended to pregnant patients starting at 28 weeks of gestation to aid with immunity against pertussis in mother and neonate after delivery.[39] Influenza and Tdap vaccination statuses are unrelated to COVID-19 vaccination status. This suggests that the fears and concerns surrounding COVID-19 vaccinations are not universal. Patients with a history of diabetes mellitus are associated with an increase in vaccination. Unlike other comorbidities, patients with diabetes mellitus require more frequent visits with a provider throughout pregnancy independent of prepregnancy control of disease to adjust medications and perform adequate fetal monitoring.[40] Perhaps the frequent visits with a provider can positively contribute to a patient's understanding and willingness to be vaccinated. Most patients in both groups prefer to learn about the vaccination via a conversation with their provider. This outlines the importance of the providers' responsibility to include well-informed counseling about the COVID-19 vaccine in routine visits. This study is limited by the small sample size. The timeframe of survey collection was limited due to research staff availability and as a result, the audience captured is small. Nevertheless, we believe that it reflects the true rates of COVID-19 vaccination in central New York. The nature of the survey was nonrandom as every patient who presented to the clinic while a research staff member was present was included. The survey was available only in English; the generalizability of these results is limited to those with English proficiency. The survey was available only via tablet and may underrepresent participants who are uncomfortable with technology, although the goal of the staff member at time of survey administration was to attempt to reduce this. Although the staff member was blinded to the answers, the presence of the staff member may increasingly contribute to a social desirability bias. Recall bias is present as the survey was not administered at the time of potential COVID-19 vaccination. The high-risk maternal fetal medicine clinic was targeted to capture a higher-risk pregnant population, but the result is a Berkson bias. Anecdotally, several patients included in this survey have been subsequently admitted while pregnant due to symptoms secondary to COVID-19 pneumonia. It would be of interest to follow up with patients to expand on number of provider visits in the past year, and if there is any information that is influencing their opinions about the vaccine since the initial survey. It would also be meaningful to evaluate if an intervention, such as provider education and talking points for provider-led conversations at routine visits, leads to a change in vaccine rates. COVID-19 vaccination opinions are dynamic throughout the natural history of the pandemic and future studies may be useful to re-evaluate patients' evolving views.
  31 in total

1.  ACOG Committee Opinion No. 741: Maternal Immunization.

Authors: 
Journal:  Obstet Gynecol       Date:  2018-06       Impact factor: 7.661

2.  COVID-19 and comorbidities: a systematic review and meta-analysis.

Authors:  Morgan Spencer Gold; Daniel Sehayek; Sofianne Gabrielli; Xun Zhang; Christine McCusker; Moshe Ben-Shoshan
Journal:  Postgrad Med       Date:  2020-07-14       Impact factor: 3.840

3.  The REDCap consortium: Building an international community of software platform partners.

Authors:  Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda
Journal:  J Biomed Inform       Date:  2019-05-09       Impact factor: 6.317

4.  Countering COVID-19 Vaccine Hesitancy in Pregnancy: the "4 Cs".

Authors:  Lydia L Shook; Thomas P Kishkovich; Andrea G Edlow
Journal:  Am J Perinatol       Date:  2021-10-19       Impact factor: 3.079

5.  COVID-19 vaccination during pregnancy: coverage and safety.

Authors:  Helena Blakeway; Smriti Prasad; Erkan Kalafat; Paul T Heath; Shamez N Ladhani; Kirsty Le Doare; Laura A Magee; Pat O'Brien; Arezou Rezvani; Peter von Dadelszen; Asma Khalil
Journal:  Am J Obstet Gynecol       Date:  2021-08-10       Impact factor: 10.693

Review 6.  Coronavirus disease 2019 (COVID-19) pandemic and pregnancy.

Authors:  Pradip Dashraath; Jing Lin Jeslyn Wong; Mei Xian Karen Lim; Li Min Lim; Sarah Li; Arijit Biswas; Mahesh Choolani; Citra Mattar; Lin Lin Su
Journal:  Am J Obstet Gynecol       Date:  2020-03-23       Impact factor: 8.661

Review 7.  COVID-19 and comorbidities: Deleterious impact on infected patients.

Authors:  Hasan Ejaz; Abdullah Alsrhani; Aizza Zafar; Humera Javed; Kashaf Junaid; Abualgasim E Abdalla; Khalid O A Abosalif; Zeeshan Ahmed; Sonia Younas
Journal:  J Infect Public Health       Date:  2020-08-04       Impact factor: 3.718

8.  COVID-19 Vaccination Coverage Among Adults - United States, December 14, 2020-May 22, 2021.

Authors:  Jill Diesel; Natalie Sterrett; Sharoda Dasgupta; Jennifer L Kriss; Vaughn Barry; Kayla Vanden Esschert; Ari Whiteman; Betsy L Cadwell; Daniel Weller; Judith R Qualters; LaTreace Harris; Achal Bhatt; Charnetta Williams; LeAnne M Fox; Dana Meaney Delman; Carla L Black; Kamil E Barbour
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-06-25       Impact factor: 17.586

9.  Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis.

Authors:  John Allotey; Elena Stallings; Mercedes Bonet; Magnus Yap; Shaunak Chatterjee; Tania Kew; Luke Debenham; Anna Clavé Llavall; Anushka Dixit; Dengyi Zhou; Rishab Balaji; Siang Ing Lee; Xiu Qiu; Mingyang Yuan; Dyuti Coomar; Jameela Sheikh; Heidi Lawson; Kehkashan Ansari; Madelon van Wely; Elizabeth van Leeuwen; Elena Kostova; Heinke Kunst; Asma Khalil; Simon Tiberi; Vanessa Brizuela; Nathalie Broutet; Edna Kara; Caron Rahn Kim; Anna Thorson; Olufemi T Oladapo; Lynne Mofenson; Javier Zamora; Shakila Thangaratinam
Journal:  BMJ       Date:  2020-09-01
View more
  1 in total

1.  COVID-19 Vaccination Status among Pregnant and Postpartum Women-A Cross-Sectional Study on More Than 1000 Individuals.

Authors:  Urszula Nowacka; Paulina Malarkiewicz; Janusz Sierdzinski; Aleksandra Januszaniec; Szymon Kozłowski; Tadeusz Issat
Journal:  Vaccines (Basel)       Date:  2022-07-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.